Nyxoah S.A.

NYXH | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.40

-$0.08 (-5.41%)

At close: Sep 22, 2026, 4:00 PM ET

$1.40

$0 (0.00%)

After-hours: Sep 22, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-5.41%

(1D)

Rating

Updated: Aug 10, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $140.1M

1D Range

1.40 1.46

52W Range

1.26 6.88

Valuation (TTM)

PE -0.58

PB 1.56

EV/EBITDA -1.09

Valuation (NTM)

Forward PE N/A

Forward PEG 0.02

Price Target $4.08

Cash Flow

FCF Yield -57.1%

SBC Adj. FCF Yield -59.1%

SBC Impact -3.6%

Margins

Gross Margin 51.3%

Operating Margin -383.1%

FCF Margin -326.1%

Growth (CAGR)

Revenue 3Y | 5Y 95.4% | 121.6%

Dil EPS 3Y | 5Y -17.4% | -16.0%

FCF 3Y | 5Y -14.7% | -12.4%

Returns

ROA -58.5%

ROE -179.7%

ROIC -59.9%

Financial Health

Net Cash

€47.09M ($53.79M)

Current Ratio 2.38

Interest Coverage -5.73

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric,...

Sector Healthcare

Industry Medical - Specialties

Employees 154

IPO Date Apr 27, 2021

Website www.nyxoah.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$3.50

Upside

+150.00%

Buy (2)

Hold (1)

Sell (0)

Analyst Details ➞